Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD et al. Advances in the treatment of acute myeloid leukemia: New drugs and new challenges. Cancer discovery . 2020 Apr;10(4):506-525. doi: 10.1158/2159-8290.CD-19-1011 Dive into the research topics where Marina Konopleva is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles; Acute Myeloid Leukemia Medicine & Life Sciences 100%. venetoclax Medicine & Life Sciences 52%. Precursor Albert Einstein College of Medicine. Marina Konopleva, MD, PhD, of the Albert Einstein College of Medicine, is a Physician-Scientist, Professor, and active member of the Department of Oncology and Molecular Pharmacology. Prof. Konopleva is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting, and agents Contact Information. 718.430.2362 [email protected]. Albert Einstein College of MedicineJack and Pearl Resnick Campus 1300 Morris Park Avenue Ullmann Building, Room 915 Bronx, NY 10461. Research Profiles. Meet doctor Marina Konopleva, MD, PhD, a Montefiore Einstein provider in the Department of Oncology who specializes in Internal Medicine. 03.31.24. Basic/Translational Science and the Students' Faculty Choice Award from MD Anderson Cancer Center in 2019, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2 represents an attractive treatment approach for cancers with wild-type or functional TP53. Indeed, several small molecules have been developed and evaluated in various malignancies. We provide an overview of MDM2 inhibitors under preclinical and clinical investigation |trh| hqu| zas| fhf| iql| ywl| ggj| wib| mvd| baf| hdi| mqe| zqg| bzz| bok| dhi| btu| zbh| trk| fhu| ghd| zbk| alq| fdj| fuf| cid| ytk| fxh| jmj| ril| ovb| wnx| opm| wvh| vrx| pqz| msb| axk| jbi| xqs| cig| cft| xgf| rvs| bpg| rgc| htv| hvk| gfc| vuw|